Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Hip Health and Mobility
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Rehabilitation Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. New, effective treatment discovered for the most difficult asthma cases

New, effective treatment discovered for the most difficult asthma cases

Stories Sep 7, 2016 3 minutes

Local researcher heads global study to help severe asthma sufferers breathe easier.

Ask 31-year-old Vancouver resident Madeline Laberge about what triggers her asthma and she’ll say with a sigh: “Basically any living thing the world”. Exposure to cats, dogs, trees, flowers, grasses, pollens, dust – the list goes on – all make breathing more challenging for Laberge whose asthma is categorized as severe and uncontrolled.

Since being diagnosed with asthma at two-and-a-half years old, Laberge has tried multiple different combinations of medications, most of which have been corticosteroids taken regularly to calm the inflammation of her airways. 

However, two years ago while participating in the CALIMA clinical trial, which was an international study that tested the efficacy of an experimental AstraZeneca asthma drug called benralizumab, Laberge felt like her life changed.

“It was like I didn’t even have asthma,” says Laberge, a respiratory therapist, of her response to the novel medication. 

“I didn’t need to take a corticosteroid for a whole year, which is unheard of in my life – I’ve never gone that long without it! And I wasn’t hospitalized for that entire year.”

According to Vancouver Coastal Health Research Institute (VCHRI) clinician scientist and global principal investigator for CALIMA Dr. Mark FitzGerald, Laberge belongs to the four per cent of asthma sufferers in British Columbia who utilize more health care resources than the average asthma patient to treat and manage their symptoms.

“In the past we haven’t had very effective treatments for this group, but benralizumab is one of a new class of non-corticosteroid asthma drugs that target a type of white blood cell called eosinophils. It’s been found that when eosinophils levels increase in your blood and airways, you’re at increased risk of having asthma exacerbations,” explains Dr. FitzGerald, director of the VCHRI Centre for Heart and Lung Health and head of the Division of Respiratory Medicine at the University of British Columbia. “Benralizumab causes eosinophils to die.”

CALIMA involved 1,306 patients aged 12 to 75 with severe asthma. The aim of the trial was to measure the effect of the drug on the annual rate of exacerbations in a sub-group of 728 patients with high eosinophils counts that are associated with the most severe form of asthma. An additional study, SIRROCO, was also completed evaluating the same medication. The SIRROCO and CALIMA studies showed that the use of benralizumab resulted in a 28 to 52 per cent reduction in rates of exacerbation, compared to placebo and also resulted in improved lung function.

“Additional therapeutic options to control severe asthma are urgently needed and our findings support the use of benralizumab as an add-on therapy for the treatment of severe asthma with persistent eosinophilia,” says Dr. FitzGerald.

“The goal of our research was to achieve the results that Madeline experienced: a controller medication given every month or two that reduces exacerbations and the need for oral corticosteroids, and results in fewer hospitalizations.”

The drug is also a novel asthma treatment in that it’s administered via an injection given to patients every four to eight weeks rather than being taken orally.

Results from both the CALIMA and SIRROCO trials were recently published in the Lancet and are being presented on September 5th at the European Respiratory Society International Congress 2016 in London.

 

Researchers

Mark FitzGerald

Related Articles

Giving voice to asthma and COPD patients

Research finds encouraging trends in B.C.’s approach to severe asthma

One in five new cases of childhood asthma in Canada are caused by traffic pollution

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Centre for Lung Health

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Stories

Early intervention with cryoablation for better heart outcomes

Jan 22, 2023 cardiac, treatment options, stroke
Type
Stories

Keeping your head in the race: Cognitive impacts observed among ultra-marathon runners

Jan 20, 2023 cardiac, cognition, safety
Type
Stories

People in profile: Barbara Allan

Jan 17, 2023 people feature
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy